[go: up one dir, main page]

WO2025176999A3 - Compounds - Google Patents

Compounds

Info

Publication number
WO2025176999A3
WO2025176999A3 PCT/GB2025/050341 GB2025050341W WO2025176999A3 WO 2025176999 A3 WO2025176999 A3 WO 2025176999A3 GB 2025050341 W GB2025050341 W GB 2025050341W WO 2025176999 A3 WO2025176999 A3 WO 2025176999A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
properties
obesity
regards
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/GB2025/050341
Other languages
French (fr)
Other versions
WO2025176999A2 (en
Inventor
Stephen Robert Bloom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Ip2ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2024/050504 external-priority patent/WO2024175930A1/en
Application filed by Ip2ipo Innovations Ltd filed Critical Ip2ipo Innovations Ltd
Publication of WO2025176999A2 publication Critical patent/WO2025176999A2/en
Publication of WO2025176999A3 publication Critical patent/WO2025176999A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.
PCT/GB2025/050341 2024-02-23 2025-02-21 Novel compounds Pending WO2025176999A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBPCT/GB2024/050504 2024-02-23
PCT/GB2024/050504 WO2024175930A1 (en) 2023-02-24 2024-02-23 Compounds

Publications (2)

Publication Number Publication Date
WO2025176999A2 WO2025176999A2 (en) 2025-08-28
WO2025176999A3 true WO2025176999A3 (en) 2025-10-02

Family

ID=94823963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2025/050341 Pending WO2025176999A2 (en) 2024-02-23 2025-02-21 Novel compounds

Country Status (1)

Country Link
WO (1) WO2025176999A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014096145A1 (en) * 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
WO2019211451A1 (en) * 2018-05-04 2019-11-07 Novo Nordisk A/S Gip derivatives and uses thereof
WO2020115049A1 (en) * 2018-12-03 2020-06-11 Antag Therapeutics Aps Modified gip peptide analogues
WO2022018186A1 (en) * 2020-07-22 2022-01-27 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
WO2024175930A1 (en) * 2023-02-24 2024-08-29 Ip2Ipo Innovations Limited Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (en) 1998-02-10 2000-03-24 Atochem Elf Sa PROCESS FOR THE PREPARATION OF AN AQUEOUS SOLUTION OF HYDROGEN PEROXIDE DIRECTLY FROM HYDROGEN AND OXYGEN AND DEVICE FOR IMPLEMENTING SAME
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014096145A1 (en) * 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
WO2019211451A1 (en) * 2018-05-04 2019-11-07 Novo Nordisk A/S Gip derivatives and uses thereof
WO2020115049A1 (en) * 2018-12-03 2020-06-11 Antag Therapeutics Aps Modified gip peptide analogues
WO2022018186A1 (en) * 2020-07-22 2022-01-27 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
WO2024175930A1 (en) * 2023-02-24 2024-08-29 Ip2Ipo Innovations Limited Compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LI YANWEI ET AL: "Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model", NEUROPHARMACOLOGY, vol. 101, 10 November 2015 (2015-11-10), pages 255 - 263, XP029336004, ISSN: 0028-3908, DOI: 10.1016/J.NEUROPHARM.2015.10.002 *
MARTIN CHRISTINE M A ET AL: "A novel acylated form of (d-Ala2)GIP with improved antidiabetic potential, lacking effect on body fat stores", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1830, no. 6, 19 March 2013 (2013-03-19), pages 3407 - 3413, XP028589266, ISSN: 0304-4165, DOI: 10.1016/J.BBAGEN.2013.03.011 *
NIGEL IRWIN ET AL: "GIP(Lys 16 PAL) and GIP(Lys 37 PAL): Novel Long-Acting Acylated Analogues of Glucose-Dependent Insulinotropic Polypeptide with Improved Antidiabetic Potential", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 3, 1 February 2006 (2006-02-01), pages 1047 - 1054, XP055044385, ISSN: 0022-2623, DOI: 10.1021/jm0509997 *
WANG LIJING: "Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP", vol. Volume 16, 25 May 2022 (2022-05-25), pages 1547 - 1559, XP055939698, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=81035> DOI: 10.2147/DDDT.S358989 *

Also Published As

Publication number Publication date
WO2025176999A2 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
US8101576B2 (en) Compounds and their effects on feeding behaviour
EP1871794B1 (en) Modified pyy(3-36) peptides and their effects on feeding behavior
US20090318347A1 (en) Novel compounds and their effects on feeding behaviour
RU2008100238A (en) COMPOUNDS OF OXYNTHOMODULIN, PHARMACEUTICAL COMPOSITION ON THEIR BASIS, METHODS OF TREATMENT AND PREVENTION OF OBESITY AND ASSOCIATED DISEASES (OPTIONS) AND MEDICINE (OPTIONS)
JP2010533157A (en) Human pancreatic polypeptide (HPP) analogs and their effects on feeding behavior
RU2017145348A (en) SELECTIVE COMPOUNDS OF PEPTIDE YY AND THEIR APPLICATIONS
AU2012210308A1 (en) Novel compounds and their effects on feeding behaviour
US20250129134A1 (en) Ham15 52 analogues with improved amylin receptor (hamy3r) potency
WO2025176999A3 (en) Compounds
WO2015177572A1 (en) Peptide yy (pyy) analogues
AU2024224775A1 (en) Compounds
US12060402B2 (en) Analogues of PYY
JP7117779B2 (en) food peptide
CN114269774A (en) Appetite suppressant compounds
WO2024112902A2 (en) Melanocortin and glp-1 receptor agonists and methods of use
Rivier et al. Competitive antagonists of peptide hormones
HK1132456A (en) Novel compounds and their effects on feeding behaviour

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25708846

Country of ref document: EP

Kind code of ref document: A2